Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prime Medicine, Inc. (Nasdaq: PRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public biotechnology company, Prime Medicine uses forms such as Form 8-K, Form 10-Q, Form 10-K and proxy statements to report material events, financial results, governance matters and other information related to its Prime Editing gene editing platform and pipeline.
Recent Form 8-K filings for Prime Medicine have covered topics such as quarterly financial results and business highlights, preliminary cash and investment balances, underwritten public offerings of common stock, option repricing approvals, changes in executive leadership, and the posting of updated corporate presentations. These filings help investors understand how the company is funding research and development for programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis and other areas, as well as how it manages equity compensation and corporate governance.
Definitive proxy materials, such as the company’s DEF 14A, describe matters submitted to stockholders, including proposals related to equity plans and special meetings. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide more detailed information on Prime Medicine’s operations, risk factors, research and development expenses, and other aspects of its business as a biotechnology issuer focused on Prime Editing-based therapies.
On Stock Titan, Prime Medicine filings are updated as they are made available through EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership roles, special stockholder meetings, and other material events disclosed in Forms 8-K and related exhibits. Users can also review filings that may include information about stock-based compensation, equity offerings, and other capital structure changes relevant to PRME shares.
Prime Medicine, Inc. has converted its shelf filing to a non-automatic Form S-3 and is registering up to
The prospectus states the base shelf covers common stock, preferred stock, debt securities, warrants and/or units, and that specific terms will be set forth in prospectus supplements. It also notes resale registration obligations for Bristol Myers Squibb of 11,006,163 shares and reports 180,514,014 shares outstanding as of December 31, 2025.
Prime Medicine, Inc. outlines its business, pipeline and key risks as a clinical-stage gene editing company using Prime Editing to create durable treatments for genetic diseases. The company focuses on liver-targeted in vivo programs for Wilson Disease (PM577) and alpha-1 antitrypsin deficiency (PM647), an early cystic fibrosis program, and an ex vivo program, PM359 for chronic granulomatous disease, which has shown restoration of functional protein activity in a Phase 1/2 study without reported serious editing-related adverse events.
The filing highlights a substantial doubt about the company’s ability to continue as a going concern because existing cash, cash equivalents and investments will not fund operations for more than one year beyond the filing date, and states that substantial additional funding will be needed. Prime Medicine reports significant strategic partnerships, including a collaboration with Bristol-Myers Squibb that brought a $55 million upfront payment plus a $55 million equity investment and potential milestones, and funding agreements with the Cystic Fibrosis Foundation. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $238,759,057, and as of February 20, 2026, there were 180,552,179 shares of common stock outstanding.
Prime Medicine, Inc. files a post-effective amendment to its Form S-3 shelf registration to update disclosure required for a registrant that will no longer be a well-known seasoned issuer and to add prospectuses for future offerings.
The filing registers up to
Prime Medicine, Inc. reported full-year 2025 results and detailed progress across its gene-editing pipeline. Total collaboration revenue was
Prime highlighted “breakthrough” Phase 1/2 data for PM359 in chronic granulomatous disease and is working toward final FDA alignment to submit a biologics license application. It plans to file IND and/or CTA applications for its Wilson Disease program PM577 in the first half of 2026 and for its Alpha-1 Antitrypsin Deficiency program PM647 in mid-2026, with initial clinical data for both targeted in 2027. The company is also advancing a cystic fibrosis program supported by the Cystic Fibrosis Foundation and continues its ex vivo CAR-T collaboration with Bristol Myers Squibb, positioning its Prime Editing platform for broader clinical validation.
Reine Allan reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Executive Officer Reine Allan received a grant of stock options for 1,300,000 shares of company stock. The options were awarded on February 26, 2026 and are held directly. They vest in substantially equal monthly installments, with 1/48 of the underlying shares vesting on each monthly anniversary of February 26, 2026, as long as Allan continues in service on each vesting date.
LEE ANN L. reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Technical Officer Lee Ann L. received a grant of stock options covering 375,000 shares of common stock. According to the terms, 1/48th of the option vests in substantially equal monthly installments starting on February 23, 2026, subject to her continued service, aligning this award with long-term employment and company performance.
Prime Medicine, Inc. reported that officer Alenson Carman acquired a stock option covering 140,000 shares of the company’s stock. This was recorded as a grant or award transaction.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of February 23, 2026, conditioned on Carman’s continued service on each vesting date.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 5,995,183 shares of Prime Medicine Inc. common stock, representing 3.3% of the class as of 12/31/2025. The firm has sole voting and dispositive power over all of these shares.
The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Prime Medicine. The filer also states that this report should not be construed as an admission that it is the beneficial owner of these securities.
Prime Medicine, Inc. furnished an updated corporate presentation on its investor website, with the materials attached as Exhibit 99.1. The presentation, dated January 2026, is provided under a Regulation FD disclosure to share information with the market in a broadly accessible way. The company states that this information is being furnished rather than filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Prime Medicine (PRME) filed its Q3 2025 10‑Q, highlighting a development‑stage profile with modest collaboration revenue and ongoing investment in programs. Total revenue was $1.2 million in the quarter, while the net loss was $50.6 million or $(0.32) per share. Year to date, revenue reached $3.8 million with a net loss of $155.1 million.
Operating expenses reflected pipeline progress and footprint expansion: R&D was $44.0 million and G&A was $11.2 million in Q3. Cash used in operations for the first nine months was $125.3 million. The balance sheet shows $71.4 million in cash and cash equivalents and $137.0 million in short‑term investments, totaling $213.3 million in cash, cash equivalents, and investments as of September 30, 2025. Management states this is sufficient to fund operations for at least twelve months from issuance.
In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share for $138.4 million in net proceeds. As of September 30, 2025, 180,309,471 shares were outstanding. Prime Medicine also recorded an $18.0 million research funding liability tied to external funding arrangements.